RATIONALE: The predictive value of longitudinal change in BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index has received limited attention. We hypothesized that decrease in a modified BODE (mBODE) would predict survival in National Emphysema Treatment Trial (NETT) patients. OBJECTIVES: To determine how the mBODE score changes in patients with lung volume reduction surgery versus medical therapy and correlations with survival. METHODS: Clinical data were recorded using standardized instruments. The mBODE was calculated and patient-specific mBODE trajectories during 6, 12, and 24 months of follow-up were estimated using separate regressions for each patient. Patients were classified as having decreasing, stable, increasing, or missing mBODE based on their absolute change from baseline. The predictive ability of mBODE change on survival was assessed using multivariate Cox regression models. The index of concordance was used to directly compare the predictive ability of mBODE and its separate components. MEASUREMENTS AND MAIN RESULTS: The entire cohort (610 treated medically and 608 treated surgically) was characterized by severe airflow obstruction, moderate breathlessness, and increased mBODE at baseline. A wide distribution of change in mBODE was seen at follow-up. An increase in mBODE of more than 1 point was associated with increased mortality in surgically and medically treated patients. Surgically treated patients were less likely to experience death or an increase greater than 1 in mBODE. Indices of concordance showed that mBODE change predicted survival better than its separate components. CONCLUSIONS: The mBODE demonstrates short- and intermediate-term responsiveness to intervention in severe chronic obstructive pulmonary disease. Increase in mBODE of more than 1 point from baseline to 6, 12, and 24 months of follow-up was predictive of subsequent mortality. Change in mBODE may prove a good surrogate measure of survival in therapeutic trials in severe chronic obstructive pulmonary disease. Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).
RATIONALE: The predictive value of longitudinal change in BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index has received limited attention. We hypothesized that decrease in a modified BODE (mBODE) would predict survival in National Emphysema Treatment Trial (NETT) patients. OBJECTIVES: To determine how the mBODE score changes in patients with lung volume reduction surgery versus medical therapy and correlations with survival. METHODS: Clinical data were recorded using standardized instruments. The mBODE was calculated and patient-specific mBODE trajectories during 6, 12, and 24 months of follow-up were estimated using separate regressions for each patient. Patients were classified as having decreasing, stable, increasing, or missing mBODE based on their absolute change from baseline. The predictive ability of mBODE change on survival was assessed using multivariate Cox regression models. The index of concordance was used to directly compare the predictive ability of mBODE and its separate components. MEASUREMENTS AND MAIN RESULTS: The entire cohort (610 treated medically and 608 treated surgically) was characterized by severe airflow obstruction, moderate breathlessness, and increased mBODE at baseline. A wide distribution of change in mBODE was seen at follow-up. An increase in mBODE of more than 1 point was associated with increased mortality in surgically and medically treated patients. Surgically treated patients were less likely to experience death or an increase greater than 1 in mBODE. Indices of concordance showed that mBODE change predicted survival better than its separate components. CONCLUSIONS: The mBODE demonstrates short- and intermediate-term responsiveness to intervention in severe chronic obstructive pulmonary disease. Increase in mBODE of more than 1 point from baseline to 6, 12, and 24 months of follow-up was predictive of subsequent mortality. Change in mBODE may prove a good surrogate measure of survival in therapeutic trials in severe chronic obstructive pulmonary disease. Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).
Authors: Frank Sciurba; Gerard J Criner; Shing M Lee; Zab Mohsenifar; David Shade; William Slivka; Robert A Wise Journal: Am J Respir Crit Care Med Date: 2003-02-20 Impact factor: 21.405
Authors: Fernando J Martinez; Gregory Foster; Jeffrey L Curtis; Gerard Criner; Gail Weinmann; Alfred Fishman; Malcolm M DeCamp; Joshua Benditt; Frank Sciurba; Barry Make; Zab Mohsenifar; Philip Diaz; Eric Hoffman; Robert Wise Journal: Am J Respir Crit Care Med Date: 2006-03-16 Impact factor: 21.405
Authors: Alfred Fishman; Fernando Martinez; Keith Naunheim; Steven Piantadosi; Robert Wise; Andrew Ries; Gail Weinmann; Douglas E Wood Journal: N Engl J Med Date: 2003-05-20 Impact factor: 91.245
Authors: Bartolome R Celli; Claudia G Cote; Jose M Marin; Ciro Casanova; Maria Montes de Oca; Reina A Mendez; Victor Pinto Plata; Howard J Cabral Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: Mark D Eisner; Paul D Blanc; Edward H Yelin; Patricia P Katz; Gabriela Sanchez; Carlos Iribarren; Theodore A Omachi Journal: Thorax Date: 2010-03 Impact factor: 9.139
Authors: Mark D Eisner; Theodore A Omachi; Patricia P Katz; Edward H Yelin; Carlos Iribarren; Paul D Blanc Journal: Chest Date: 2009-12-29 Impact factor: 9.410
Authors: Roberto Benzo; Wendy Siemion; Paul Novotny; Alice Sternberg; Robert M Kaplan; Andrew Ries; Robert Wise; Fernando Martinez; James Utz; Frank Sciurba Journal: J Pain Symptom Manage Date: 2013-03-21 Impact factor: 3.612
Authors: Louis Laviolette; Francesco Sava; Denis E O'Donnell; Katherine A Webb; Alan L Hamilton; Steven Kesten; François Maltais Journal: BMC Pulm Med Date: 2010-05-30 Impact factor: 3.317
Authors: José Luis Lopez-Campos; Pilar Cejudo; Eduardo Marquez; Francisco Ortega; Esther Quintana; Carmen Carmona; Emilia Barrot Journal: Int J Chron Obstruct Pulmon Dis Date: 2010-05-06
Authors: Neeta Thakur; Paul D Blanc; Laura J Julian; Edward H Yelin; Patricia P Katz; Stephen Sidney; Carlos Iribarren; Mark D Eisner Journal: Int J Chron Obstruct Pulmon Dis Date: 2010-09-07
Authors: M D Eisner; P D Blanc; T A Omachi; E H Yelin; S Sidney; P P Katz; L M Ackerson; G Sanchez; Irina Tolstykh; C Iribarren Journal: J Epidemiol Community Health Date: 2009-10-23 Impact factor: 3.710
Authors: Mark D Eisner; Carlos Iribarren; Edward H Yelin; Stephen Sidney; Patricia P Katz; Gabriela Sanchez; Paul D Blanc Journal: Int J Chron Obstruct Pulmon Dis Date: 2009-05-07